<DOC>
	<DOCNO>NCT00805610</DOCNO>
	<brief_summary>The investigator research examine safety efficacy hepatocyte transplantation patient acute liver failure without history chronic disease . The investigator study effectiveness provide bridge support patient survival whole organ transplantation possible . This support may also bridge recovery ; allow native liver recover orthotopic liver transplant necessary . The investigator also study safety efficacy hepatocyte transplantation patient chronic liver disease . Underlying etiology chronic disease may arise cirrhosis , fibrosis inherit metabolic disorder . The investigator examine cell transplantation end-stage patient eligible whole organ transplant . These patient may benefit amelioration symptom allow therapeutic treatment . The investigator study also examine ability transplant hepatocytes treat inherit metabolic disease ( ex. , Crigler-Najjar Disease , Familial Hypercholesterolemia , Urea Cycle Disorders ) . Cell transplant may also act 'bridge ' whole organ transplant improve function , permit easy disease control traditional therapy .</brief_summary>
	<brief_title>Hepatocyte Transplantation Liver Failure</brief_title>
	<detailed_description />
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<criteria>Inclusion criterion specific classification liver disease , i.e. , fulminant nonfulminant metabolic disease Any systemic infection Unstable coronary artery disease HIV infection Preformed antibodies class antigen present available donor sample ( Only cell ABOcompatible donor HLA Class I antigen recipient preform antibody select transplant . ) Hepatopulmonary disease ( Room air Pa02 â‰¤ 60 mmHg ) Testing positive Hepatitis B Surface Antigen ( HBsAg ) , Hepatitis Be antigen ( HBeAg ) Hepatitis B Virus DNA unable receive pay Hepatitis B treatment . Any current anticipated contraindication use tacrolimus cyclosporine , methylprednisolone prednisone . Female patient breast feed Any medical condition , opinion investigator , make patient unsuitable participation trial .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Liver Failure</keyword>
	<keyword>Hepatocyte Transplantation</keyword>
	<keyword>Liver Transplantation</keyword>
</DOC>